Skip to main content

Table 1 Comparison of global outcome measures, comparing basal (pre) and after one year (post) on a GFD: Change is calculated as the percentage improvement in scores

From: Clinical impact of a gluten-free diet on health-related quality of life in seven fibromyalgia syndrome patients with associated celiac disease

 

Pre-GFD

Post-GFD

Change (%)

P

TPs (scale 0–18)

16.3 (2.4)

8.0 (1.6)

8.3 (51)

< 0.001

FIQ (scale 0–80)

74.3 (2.9)

36.6 (4.0)

37.7 (51)

< 0.001

HAQ (scale 0–3)

1.7 (0.6)

0.7 (0.3)

1.0 (52)

< 0.001

VAS digestive (scale 0–100)

47.8 (2.4)

19.1 (0.8)

28.7 (60)

< 0.001

VAS pain (scale 0–10)

8.0 (0.5)

3.9 (1.0)

4.1 (52)

< 0.001

VAS fatigue (scale 0–10)

7.9 (0.3)

3.9 (0.8)

4.0 (51)

< 0.001

SF36-PCS (scale 0–100)

27.4 (3.6)

40.4 (5.1)

+13.0 (48)

< 0.001

SF36-MCS (scale 0–100)

17.4 (2.9)

27.8 (3.3)

+10.4 (60)

< 0.001

Prescribed drugs (N)

6.6 (1.5)

3.3 (0.5)

3.6 (55)

< 0.001

tTG2 (U/ml)

60.4 (52.2)

0.7 (0.2)

59.7 (98)

< 0.05

  1. Data are expressed as mean and standard deviation. TPs Tender Points. FIQ Fibromyalgia Impact Questionnaire. HAQ Health Assessment Questionnaire. VAS Visual Analogue Scale. SF-36 Short Form Health Survey; PCS Physical Component Summary; MCS Mental Component Summary. N number. tTG-2 Tissue Trans-Glutaminase-2. P < 0.05, significant; P < 0.001, highly significant.